QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

GX Acquisition (GXGX) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

GXGX vs. SYBX, EDSA, PIRS, MBRX, LABP, FBIO, NCNA, MIRA, PPBT, and RDHL

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Synlogic (SYBX), Edesa Biotech (EDSA), Pieris Pharmaceuticals (PIRS), Moleculin Biotech (MBRX), Landos Biopharma (LABP), Fortress Biotech (FBIO), NuCana (NCNA), MIRA Pharmaceuticals (MIRA), Purple Biotech (PPBT), and RedHill Biopharma (RDHL). These companies are all part of the "medical" sector.

GX Acquisition vs.

Synlogic (NASDAQ:SYBX) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

GX Acquisition has lower revenue, but higher earnings than Synlogic.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$1.18M14.56-$66.15M-$12.76-0.15
GX AcquisitionN/AN/A-$49.26MN/AN/A

GX Acquisition has a net margin of 0.00% compared to GX Acquisition's net margin of -8,396.04%. GX Acquisition's return on equity of -95.30% beat Synlogic's return on equity.

Company Net Margins Return on Equity Return on Assets
Synlogic-8,396.04% -95.30% -67.97%
GX Acquisition N/A -985.20%-6.02%

In the previous week, Synlogic had 3 more articles in the media than GX Acquisition. MarketBeat recorded 3 mentions for Synlogic and 0 mentions for GX Acquisition. GX Acquisition's average media sentiment score of 0.83 beat Synlogic's score of 0.00 indicating that Synlogic is being referred to more favorably in the media.

Company Overall Sentiment
Synlogic Positive
GX Acquisition Neutral

Synlogic received 329 more outperform votes than GX Acquisition when rated by MarketBeat users. However, 100.00% of users gave GX Acquisition an outperform vote while only 69.68% of users gave Synlogic an outperform vote.

CompanyUnderperformOutperform
SynlogicOutperform Votes
331
69.68%
Underperform Votes
144
30.32%
GX AcquisitionOutperform Votes
2
100.00%
Underperform Votes
No Votes

47.2% of Synlogic shares are owned by institutional investors. Comparatively, 61.7% of GX Acquisition shares are owned by institutional investors. 8.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Synlogic has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Synlogic currently has a consensus price target of $65.00, suggesting a potential upside of 3,375.94%. Given GX Acquisition's higher probable upside, equities analysts plainly believe Synlogic is more favorable than GX Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synlogic
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Synlogic beats GX Acquisition on 9 of the 14 factors compared between the two stocks.


Get GX Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXGX vs. The Competition

MetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$14.88M$6.52B$4.96B$7.45B
Dividend YieldN/A2.64%2.90%3.88%
P/E RatioN/A10.36225.8416.90
Price / SalesN/A171.933,032.6664.65
Price / CashN/A19.7194.9854.63
Price / Book2.964.814.474.66
Net Income-$49.26M$152.42M$112.56M$210.60M

GX Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYBX
Synlogic
3.4317 of 5 stars
$1.83
+1.7%
$65.00
+3,451.9%
-83.0%$16.82M$1.18M-0.1472Positive News
Gap Down
EDSA
Edesa Biotech
3.5933 of 5 stars
$5.36
-0.2%
$39.00
+627.6%
-49.7%$16.99MN/A0.0016Short Interest ↓
Positive News
PIRS
Pieris Pharmaceuticals
2.9776 of 5 stars
$0.17
+6.3%
N/A-89.3%$16.72M$25.90M-0.48127Analyst Report
Short Interest ↓
MBRX
Moleculin Biotech
3.6336 of 5 stars
$0.50
flat
$8.00
+1,500.3%
-49.7%$16.70MN/A-0.5515Analyst Report
LABP
Landos Biopharma
0 of 5 stars
$5.73
+2.3%
N/A+67.6%$17.86M$18M-1.5222Positive News
High Trading Volume
FBIO
Fortress Biotech
2.4587 of 5 stars
$1.78
-4.3%
$55.00
+2,989.9%
-82.4%$15.91M$75.74M-0.15187Short Interest ↑
NCNA
NuCana
3.4848 of 5 stars
$0.34
-2.8%
$5.00
+1,357.7%
-74.6%$17.94MN/A-0.4228Short Interest ↓
News Coverage
Gap Up
MIRA
MIRA Pharmaceuticals
0.4673 of 5 stars
$1.07
+2.9%
N/AN/A$15.82MN/A0.002Short Interest ↑
PPBT
Purple Biotech
2.9831 of 5 stars
$0.72
-5.3%
$9.00
+1,157.9%
-66.3%$15.76MN/A-0.6720Analyst Report
News Coverage
RDHL
RedHill Biopharma
0 of 5 stars
$0.53
-3.6%
N/A-94.1%$15.72M$61.80M0.00113Short Interest ↓
Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:GXGX) was last updated on 2/28/2024 by MarketBeat.com Staff